CliffBio
biologic

Entyvio

vedolizumab

Loss of exclusivitySeptember 2035projected — 12-year biologic exclusivity estimate
CompanyTakeda Pharmaceuticals U.S.A., Inc.

Drug detail

Brand nameEntyvio
Active ingredientvedolizumab
Strength108MG/0.68ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalSeptember 2023
Marketing statusRx

More from Takeda Pharmaceuticals U.S.A., Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.